HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone.

AbstractINTRODUCTION:
The optimal dose of samarium-153-EDTMP (153Sm-EDTMP) for effective palliation of painful metastases to bone is under investigation. It is not known whether increased doses of 153Sm EDTMP will lead to better and longer pain and tumour control and survival. Multiple dose efficacy and toxicity is of importance as most Patients will require prolonged support for pain.
METHODS:
Twenty-eight (28) patients were treated with 0.75 mCi/kg, 35 patients with 1.5 mCi/kg and 19 patients with 3 mCi/kg in three sequential Phase I-II trials. Multiple doses were given to patients on the 0.75 mCi/kg and 1.5 mCi/kg dose levels.
RESULTS:
At all dose levels adequate pain control was achieved in 78-95% of patients. The duration of pain control was 40-56 days with the best results in the 1.5 mCi/kg group (56 days). There is no evidence that increasing dose leads to better and longer pain control, tumour response and survival, but toxicity is increased. Multiple doses can be given with acceptable toxicity and pain control, however, only 38% of patients will qualify for multiple treatments.
CONCLUSION:
153Sm-EDTMP provides adequate and safe palliation but multiple doses can only be given in 38% of patients. There is not a clear dose-response relationship. The length of pain control is satisfactory but not ideal and hospitalisation for 4 days every 6-8 weeks is a disadvantage. Further research is required to combine 153Sm-EDTMP with cytostatics and to administer it on an out patient basis.
AuthorsA S Alberts, B J Smit, W K Louw, A J van Rensburg, A van Beek, V Kritzinger, J S Nel
JournalRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Radiother Oncol) Vol. 43 Issue 2 Pg. 175-9 (May 1997) ISSN: 0167-8140 [Print] Ireland
PMID9192964 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Organometallic Compounds
  • Organophosphorus Compounds
  • Radioisotopes
  • Samarium
  • samarium Sm-153 lexidronam
Topics
  • Bone Neoplasms (radiotherapy, secondary)
  • Dose-Response Relationship, Radiation
  • Humans
  • Middle Aged
  • Organometallic Compounds (administration & dosage, adverse effects)
  • Organophosphorus Compounds (administration & dosage, adverse effects)
  • Pain (etiology)
  • Pain Management
  • Palliative Care
  • Radioisotopes (administration & dosage, adverse effects)
  • Radiotherapy Dosage
  • Samarium (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: